Talk about a win-win
In June 2021, the FDA approved Wegovy for chronic weight management for adults with obesity (BMI 30kg/m2) or overweight (BMI 27kg/m2) and related comorbidities with at least one weight-related comorbidity, to be administered subcutaneously at 2.4mg once weekly
You might be a good fit if: You have a BMI of 30 or higher (obesity) You have a BMI of 27 or higher plus at least one weight-related health condition like high blood pressure, high cholesterol, or type 2 diabetes You've tried diet and exercise but still struggle with significant weight issues You don't have a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 But there are some subtle differences in who might do better with one medication versus the other
This wasnt the only example of the so-called Sleep Chicken Challenge or the hashtag #SleepyChicken on social media
A higher dose of Wegovy (7.2 mg) was approved by the MHRA in January 2026 following the STEP UP trial, which showed: 2 Wegovy 7.2 mg: 20.7% average weight loss Wegovy 2.4 mg: 17.5% average weight loss 50.9% of those on 7.2 mg lost at least 20% of body weight The 7.2 mg dose is not a starting dose
Patients should aim for adequate fluid intake (individualized based on their specific needs and medical conditions) and consume electrolyte-rich foods or beverages, particularly during dose escalation periods
